Jun Hee-Sook, Park Eun-Young
Lee Gil Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science, Incheon, Korea.
Int J Stem Cells. 2009 May;2(2):115-21. doi: 10.15283/ijsc.2009.2.2.115.
Diabetes mellitus is a metabolic disorder resulting from an inadequate mass of insulin-producing pancreatic beta cells. The replacement or restoration of damaged beta cells would be considered the optimal therapeutic options. Islet transplantation seems to be a promising approach for replacement therapy; however, the main obstacle is the shortage of organ donors. As mature beta cells have been shown to be difficult to expand in vitro, regeneration of beta cells from embryonic or adult stem cells or pancreatic progenitor cells is an attractive method to restore the islet cell mass. So far, multiple studies using various strategies have shown direct differentiation of stem and progenitor cells toward insulin-producing cells. The important issue to be solved is how to differentiate these cells into mature functional insulin-producing cells. Further research is required to understand how endogenous beta cells differentiate and to develop methods to regenerate enough functional beta cells for clinically applicable therapies for diabetes.
糖尿病是一种由于产生胰岛素的胰腺β细胞数量不足而导致的代谢紊乱疾病。受损β细胞的替代或恢复被认为是最佳治疗选择。胰岛移植似乎是一种有前景的替代疗法;然而,主要障碍是器官供体短缺。由于已证明成熟β细胞在体外难以扩增,从胚胎或成体干细胞或胰腺祖细胞再生β细胞是恢复胰岛细胞数量的一种有吸引力的方法。到目前为止,多项采用各种策略的研究已表明干细胞和祖细胞可直接分化为产生胰岛素的细胞。有待解决的重要问题是如何将这些细胞分化为成熟的功能性产生胰岛素的细胞。需要进一步研究以了解内源性β细胞如何分化,并开发出能够再生足够数量功能性β细胞的方法,用于糖尿病的临床适用治疗。